Novel Therapies in the Treatment of Cancer: The Emerging Role of Immunotherapies
This educational activity explores the growing role of immunotherapy in treating patients with both hematologic and solid tumor malignancies. Approvals for novel indications as well as place in therapy and association with biomarkers predictive of response are discussed. Patient cases are utilized to highlight therapy selection as well as common adverse effects. Specific focus also includes toxicity management strategies.
Agenda
Welcome and Introductions
Christine Walko, Pharm.D.
Current Immunotherapy Approvals and Place in Therapy
Christine Walko, Pharm.D.
Predictors of Response for Immunotherapy
Christine Walko, Pharm.D.
Future Directions in Place in Therapy
Ragini Kudchadkar, M.D
Toxicity Management of Immunotherapy
Ragini Kudchadkar, M.D
Faculty Discussion and Audience Questions
Learning Objectives
- Evaluate the current and future places in therapy for immunotherapy agents, including novel indications in both hematologic and solid tumor malignancies.
- Identify common toxicities associated with immunotherapy and recommend best practices for their management.
- Apply strategies for the appropriate selection of immunotherapy in patient scenarios, including consideration of biomarkers and unique patient characteristics.
Target Audience
This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in the treatment of cancer patients with immunotherapies.
Format
This online activity consists of slide presentations, active learning, an assessment, and evaluation. View the system requirements.
Disclosure Statement
In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.
In this activity, only the individuals below has disclosed a relevant financial relationship. No other persons associated with this presentation have disclosed any relevant financial relationships.
Christine M. Walko, Pharm.D., BCOP, FCCP
- Bristol-Myers Squibb and Merck: Honoraria received for participation in the Institute for Clinical Immuno-Oncology’s Melanoma Board
Ragini R. Kudchadkar, M.D
- Bristol-Myers Squibb: Advisory Board member
- Merck: Research funding received
Claim CE within 60 Days
Participants should claim CE credit for this home-study activity only if they have not claimed credit for the live activity.
To receive CE credit, complete the steps below within 60 days of completing the activity.
- View entire presentation and answer all polling questions.
- Click "Complete Activity" on the last slide to complete the assessment and evaluation.
- Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
After the 60-day deadline, ASHP will no longer be able to report credit(s).
Accreditation for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE #: 0204-0000-17-438-H01-P
Release Date: March 1, 2018
Expiration Date: May 21, 2019
Activity Type: Application-based
CE Credits: 1.5, no partial credit for pharmacists
Activity Fee: Free of charge
CME Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Christine M. Walko, Pharm.D., BCOP, FCCP, Activity Chair
Ragini R. Kudchadkar, M.D.